155 related articles for article (PubMed ID: 37272079)
21. Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison.
Harlin M; Chepke C; Larsen F; Bell Lynum KS; Chumki SR; Fitzgerald H; Such P; Madera-McDonough J; Yildirim M; Panni M; Saklad SR
Neuropsychiatr Dis Treat; 2023; 19():1409-1416. PubMed ID: 37313228
[TBL] [Abstract][Full Text] [Related]
22. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy.
Baune BT
Curr Med Res Opin; 2024 Jan; 40(1):87-96. PubMed ID: 37999650
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
24. Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
Mazza M; Squillacioti MR; Pecora RD; Janiri L; Bria P
Expert Opin Pharmacother; 2008 Dec; 9(18):3145-9. PubMed ID: 19040335
[TBL] [Abstract][Full Text] [Related]
25. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.
Vieta E; Mullen J; Brecher M; Paulsson B; Jones M
Curr Med Res Opin; 2005 Jun; 21(6):923-34. PubMed ID: 15969892
[TBL] [Abstract][Full Text] [Related]
26. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
[TBL] [Abstract][Full Text] [Related]
27. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
McElroy SL; Suppes T; Frye MA; Altshuler LL; Stanford K; Martens B; Leverich GS; Post RM; Keck PE
J Affect Disord; 2007 Aug; 101(1-3):275-81. PubMed ID: 17229469
[TBL] [Abstract][Full Text] [Related]
28. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.
Juruena MF; Ottoni GL; Machado-Vieira R; Carneiro RM; Weingarthner N; Marquardt AR; Fleig SS; Broilo L; Busnello EA
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):94-9. PubMed ID: 19007842
[TBL] [Abstract][Full Text] [Related]
29. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
[TBL] [Abstract][Full Text] [Related]
30. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.
Perlis RH; Baker RW; Zarate CA; Brown EB; Schuh LM; Jamal HH; Tohen M
J Clin Psychiatry; 2006 Nov; 67(11):1747-53. PubMed ID: 17196055
[TBL] [Abstract][Full Text] [Related]
31. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
Keck PE; Calabrese JR; McIntyre RS; McQuade RD; Carson WH; Eudicone JM; Carlson BX; Marcus RN; Sanchez R;
J Clin Psychiatry; 2007 Oct; 68(10):1480-91. PubMed ID: 17960961
[TBL] [Abstract][Full Text] [Related]
32. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.
Ishigooka J; Nakamura J; Fujii Y; Iwata N; Kishimoto T; Iyo M; Uchimura N; Nishimura R; Shimizu N;
Schizophr Res; 2015 Feb; 161(2-3):421-8. PubMed ID: 25556976
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.
Schöttle D; Janetzky W; Luedecke D; Beck E; Correll CU; Wiedemann K
BMC Psychiatry; 2018 Nov; 18(1):365. PubMed ID: 30428862
[TBL] [Abstract][Full Text] [Related]
35. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
[TBL] [Abstract][Full Text] [Related]
36. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.
Chwieduk CM; Scott LJ
CNS Drugs; 2011 Mar; 25(3):251-67. PubMed ID: 21323396
[TBL] [Abstract][Full Text] [Related]
37. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.
Tohen M; McDonnell DP; Case M; Kanba S; Ha K; Fang YR; Katagiri H; Gomez JC
Br J Psychiatry; 2012 Nov; 201(5):376-82. PubMed ID: 22918966
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
Calabrese JR; Durgam S; Satlin A; Vanover KE; Davis RE; Chen R; Kozauer SG; Mates S; Sachs GS
Am J Psychiatry; 2021 Dec; 178(12):1098-1106. PubMed ID: 34551584
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
